Efficacy and safety of neuromodulators combined with proton pump inhibitors for non-erosive reflux disease: A randomized clinical trial

doi:10.3748/wjg.122876

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 32, Issue 44

This Article

(1)

(0)

(1)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Randomized Clinical Trial

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastroenterol. Nov 28, 2026; 32(44): 122876
Published online Nov 28, 2026. doi: 10.3748/wjg.122876

Table 4 Cost-effectiveness between the two groups over 12 weeks

Parameters	FM + LPZ group	P + LPZ group
Unit costs (USD)
LPZ (per tablet)	1.1	1.1
FM/placebo (per tablet)	0.1	0.0
Outpatient clinic visit (per visit)	7.0	7.0
Resource utilization (mean per patient)
Initial 2-week therapy (days)	14	14
On-demand therapy (days)	8.2	21.3
Outpatient clinic visits (times)	2	3
Cost-effectiveness
Total cost (USD)	40.6	59.8
CER (USD/treatment response rate)	47.5	95.2
ICER (USD/treatment response rate)	-84.6

Placebo tablets were produced at negligible cost and were therefore not included in the cost calculation. FM: Flupentixol-melitracen; LPZ: Lansoprazole; P + LPZ: Lansoprazole plus placebo; USD: United States dollars; CER: Cost-effectiveness ratio; ICER: Incremental cost-effectiveness ratio.

Full Size Table

Citation: Yin KH, Wang XY, Wang XY, Cheng L, Wang B, Wang QQ, Qiao Y, Tang XR, Yan XJ, Chen SL. Efficacy and safety of neuromodulators combined with proton pump inhibitors for non-erosive reflux disease: A randomized clinical trial. World J Gastroenterol 2026; 32(44): 122876
URL: https://www.wjgnet.com/1007-9327/full/v32/i44/122876.htm
DOI: https://dx.doi.org/10.3748/wjg.122876

Yin KH, Wang XY, Wang XY, Cheng L, Wang B, Wang QQ, Qiao Y, Tang XR, Yan XJ, Chen SL. Efficacy and safety of neuromodulators combined with proton pump inhibitors for non-erosive reflux disease: A randomized clinical trial. World J Gastroenterol 2026; 32(44): 122876 [DOI: 10.3748/wjg.122876]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.